Fund manager pleads guilty to insider trading

Former FrontPoint fund manager Joseph Skowron pleaded guilty to an insider trading charge related to Human Genome Sciences' hepatitis C drug. Skowron received tips on clinical trials outcomes from hepatitis C expert and former HGS advisor Yves Benhamou that helped his fund avoid more than $30 million in losses, according to Bloomberg. Report

Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.